The National Cancer Center (NCC) has signed a memorandum of understanding with the U.S. National Cancer Institute (NCI) to research proteogenomics jointly.
|NCI's Director of Cancer Clinical Proteomics Research Henry Rodriguez (left) and NCC President Lee Eun-sook signed a partnership agreement, during the 13th National Cancer Center International Symposium at the National Cancer Center in Goyang, Gyeonggi Province, on Friday.|
The two national cancer centers signed the agreement during the 13th National Cancer Center International Symposium held at the NCC Hospital on Friday.
Through this agreement, NCI will provide technical support for the introduction of the proteogenomics global research standard at NCC, while the latter will share the results of its proteogenomics analysis of the local biliary, gastric, cervical and breast cancer patients.
"Research collaboration with NCC, which has excellent analytical skills and resources for proteogenomics, will enable the identification of more reliable biomarkers for a variety of carcinomas and ultimately take a major step forward in cancer conquest," said Henry Rodriguez, director of U.S. National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research.
NCI already has a long partnership with NCC and the MOU is another series in that long partnership, he added.
Rodriguez stressed that he hopes that something positive will come out of the partnership that does not just benefit the Korean population but all cancer patients.
<© Korea Biomedical Review, All rights reserved.>